Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies.
about
Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide ReceptorPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.A β-peptide agonist of the GLP-1 receptor, a class B GPCR.Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.Phytochemical and Biological Evaluations of Arum hygrophilum Boiss. (Araceae)A link between hepatic glucose production and peripheral energy metabolism via hepatokinesGLP-1 based therapeutics: simultaneously combating T2DM and obesity.TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity.The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.Peripheral targets in obesity treatment: a comprehensive update.New perspectives on the development of antiobesity drugs.Islet α cells and glucagon--critical regulators of energy homeostasis.Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction.GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice.Antiobesity and antihyperglycaemic effects of Adiantum capillus-veneris extracts: in vitro and in vivo evaluations.Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice.
P2860
Q27678197-68AC917F-14E5-4729-B9F4-37130F4A7256Q30597265-7FDFBFB3-8835-4C6B-B597-2A86D85F2F87Q33553641-44A3294D-0E9C-4294-A711-2941938D043FQ33600478-6987ED9A-287D-48A0-A139-E0EC9A7CD7F9Q33647301-B21E0A67-BBA8-4D0A-AF6A-FF4808A2F3C7Q33906438-50D08E6E-646A-456E-A62D-C457D77E056BQ35200252-56FF6B7D-3BE7-4A15-BB52-F0665F659509Q37414989-BAFBE7F4-D2A7-4E09-8735-EE28DDF6E2D7Q38101677-8CACE211-A83A-4A3A-9F70-EE2C9BF14793Q38194649-3B458BD5-93B1-4CBA-B70B-FA0F16164639Q38397340-72CFA40A-3993-4174-B6B6-A3A1B0A530C8Q38409880-A29B4136-76D0-490D-BD94-8BDBDAE17CB2Q38830154-6F65ABCA-0F3F-4A69-B3C7-ED0951142A91Q42170069-9F2CFE38-31A7-4DC9-8DC1-AC3CDEEAA937Q47745704-C8236311-4748-4358-A3B6-0CE0756A5BE9Q51278737-FFB9997C-2C58-45C0-82E6-E4D425364527Q53662159-B2FE6D7E-0D25-4EBC-BD1D-68599775BE47
P2860
Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Outstanding Scientific Achieve ...... lized combinatorial therapies.
@en
type
label
Outstanding Scientific Achieve ...... lized combinatorial therapies.
@en
prefLabel
Outstanding Scientific Achieve ...... lized combinatorial therapies.
@en
P2860
P356
P1433
P1476
Outstanding Scientific Achieve ...... lized combinatorial therapies.
@en
P2093
Richard D DiMarchi
P2860
P304
P356
10.2337/DB12-0272
P407
P577
2012-06-01T00:00:00Z